🇺🇸 FDA
Patent

US 8785442

Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof

granted A61PA61P13/00A61P13/12

Quick answer

US patent 8785442 (Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof) held by Curegenix, Inc. expires Mon Jul 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Curegenix, Inc.
Grant date
Tue Jul 22 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61P, A61P13/00, A61P13/12, A61P25/00, A61P31/00